October 31, 2025 Sophia Vida
Breaking News

BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers

Key Takeaways Superior healing with BioRetain® (BR-AC) — In the randomized trial, the probability of complete, lasting closure was 53% with BR-AC vs 31% with standard care, demonstrating a clear clinical benefit. Rigorous design focused on hard-to-heal DFUs — Multicenter RCT (11 U.S. sites) used a 2-week run-in; patients improving >30% on standard care were … Continue reading “BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers”